MedTrace Logo

Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

NCT07416240 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-18

No results posted yet for this study

Summary

This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer.

This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.

Conditions

  • Advanced Pancreatic Cancer

Interventions

BIOLOGICAL

Claudin18.2 Targeted Activated Dendritic Cells

Autologous dendritic cells (DCs) genetically modified to express Claudin18.2 chimeric antigen receptor (CAR) and activation domain

BIOLOGICAL

Claudin18.2 Targeted CAR-T Cells

Autologous T cells genetically modified to express Claudin18.2 chimeric antigen receptor (CAR)

Sponsors & Collaborators

  • Frontiergate Biopharm（Hainan） Co., LTD

    collaborator INDUSTRY

  • Hainan Cancer Hospital

    lead OTHER

Principal Investigators

  • HAIFENG LIN · Hainan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-18
Primary Completion
2028-02-18
Completion
2028-08-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416240 on ClinicalTrials.gov